| Q24654139 | A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire |
| Q37847257 | Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma |
| Q73184478 | Bilateral breast masses as initial presentation of widely metastatic melanoma |
| Q54791477 | Can cancer registries show whether treatment is contributing to survival increases for melanoma of the skin at a population level? |
| Q77839287 | Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? |
| Q93159934 | Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial |
| Q77763329 | Desmoplastic malignant melanoma: diagnosis of early clinical lesions |
| Q36622290 | Diagnosis and treatment of malignant melanoma of the foot |
| Q45889419 | Immunotherapy and experimental approaches for metastatic melanoma |
| Q36113681 | Leg ulcers of unusual causes |
| Q37416083 | Met amplification and tumor progression in Cdkn2a-deficient melanocytes |
| Q33879931 | Oral mucosal melanoma: epidemiology and pathobiology |
| Q35603108 | Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. |
| Q42571550 | Pancreatic resection for metastatic melanoma |
| Q37531855 | Pediatric melanoma: a review |
| Q44736830 | Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma |
| Q38942422 | Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review |
| Q34005661 | Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. |
| Q57569703 | Targeting angiogenesis in melanoma |